Drug Profile
Research programme: p75 ligands - PharmatrophiX
Latest Information Update: 29 Dec 2022
Price :
$50
*
At a glance
- Originator PharmatrophiX
- Class Small molecules
- Mechanism of Action Amyloid beta-protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Alzheimer's disease
Most Recent Events
- 29 Dec 2022 Research programme for p75 ligands is still in preclinical phase for Alzheimer's disease in USA
- 28 Jun 2020 No recent reports of development identified for preclinical development in Alzheimer's-disease in USA (PO)
- 09 Feb 2011 Elan discontinues development of P75 ligands